August 23, 2025Cancer ScienceOpen Access

Head and Neck Cancer Immunotherapy: Overcoming Limitations and Enhancing Efficacy

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Review reveals challenges and strategies in immunotherapy for HNSCC, suggesting advancements to improve therapy response.

Extensive research on immunotherapy has shown modest response rates of 15%–20% for advanced HNSCC.
Emerging strategies such as T-cell receptor-engineered therapy and tumor antigen-targeted vaccines aim to enhance immunity in tumors.
Immunomodulatory agents are promising for improving immune checkpoint inhibitor efficacy in the immunosuppressive tumor microenvironment.
Identifying biomarkers like PD-L1 is essential for predicting treatment response in head and neck cancer patients.

Shibata et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark